On
The conclusion of the study is that the mouth spray ColdZyme can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro, by 98.3% and 99.9% respectively. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that ColdZyme might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26554
For more information, please contact:
Phone: +44 7780 22 8385 | E-mail: claus.egstrand@enzymatica.com
Phone: +46 (0)701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com
About
conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in 15 countries on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in
Enzymatica AB Ideon Science Park, SE-223 70
https://news.cision.com/enzymatica-ab/r/the-journal-of-medical-virology-has-peer-reviewed--approved-and-published-the-results-of-enzymatica-,c3203735
https://mb.cision.com/Main/18091/3203735/1311400.pdf
(c) 2020 Cision. All rights reserved., source